Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 64 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
2. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
3. Cita con resumen
4. Cita con resumen
Anónimo. GAO finds gaps In FDA’s drug-tracking system. DIA Daily 2016:15 de enero. [Ref.ID 99971]
5. Cita con resumen
Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]
6. Cita con resumen
Anónimo. What next for the malaria RTS,S vaccine candidate?. Lancet 2015;386:1708. [Ref.ID 99666]
7. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
8. Cita con resumen
Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]
9. Cita con resumen
Herman O. FDA advisers vote to keep black-box warning on Chantix. Journal Watch 2014:20 de octubre. [Ref.ID 98122]
10. Cita con resumen
Anónimo. Xolair (omalizumab): drug safety communication - Slightly elevated risk of cardiovascular and cerebrovascular serious adverse events. FDA U.S. Food and Drug Administration 2014:26 de septiembre. [Ref.ID 97997]
11. Cita con resumen
Anónimo. FDA approves naloxegol for opioid-induced constipation. DIA Daily 2014:17 de septiembre. [Ref.ID 97910]
14. Cita con resumen
Toussaint B. EU clinical trial regulation. Lancet 2013;381:1719-20. [Ref.ID 95444]
16. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
17.Tiene citas relacionadas Cita con resumen
Anónimo. My experience in the drug industry. BMJ 2012;344:28. [Ref.ID 93249]
18.Tiene citas relacionadas Cita con resumen
Gale E. Post-marketing studies of new insulins: science or sales?. BMJ 2012;344:24-7. [Ref.ID 93248]
19.
Qato DM, Alexander GC. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. JAMA 2011;306:1595-6. [Ref.ID 91546]
20.Enlace a cita original
Blake KV, Prilla S, Accadebled S, Guimier M, Biscaro M, Persson I, Arlett P, Blackbum S, Fitt H. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2011;20:1021-9. [Ref.ID 91521]
Seleccionar todas
 
 1 a 20 de 64 siguiente >>